Home Clinical Trials Update

Clinical Trials Update

Study Meets Primary Endpoint: Enfortumab Vedotin Significantly Improves Overall Survival in Urothelial Cancer

A phase III trial of enfortumab vedotin (enfortumab vedotin-ejfv; Padcev®; Seattle Genetics/Astellas) met its primary endpoint of overall survival...
ESMO 2017 - 3

ESMO 2020: Sacituzumab Govitecan Shows Encouraging Early-Stage Clinical Results in Brain Cancer

A clinical trial (NCT03995706) studying the extent by which sacituzumab govitecan (Trodelvy™; Immunomedics) is able to get into the...

ESMO 2020: Updated Interim Data of XMT-1536 Supports Continued Development in Ovarian Cancer

Updated interim phase I date for the safety, tolerability, and efficacy porting for the ovarian cancer cohort of an...

First Patients Dosed in Phase II Study of Patritumab Deruxtecan in HER3 Expressing Advanced...

A first patient was doses in a phase II clinical trial designed to evaluate patritumab deruxtecan (previously known as...

Merck & Co and Seattle Genetics Sign Exclusive Licensing and Co-Development Agreement

Merck & Co and Seattle Genetics have signed an exclusive licensing and co-developing agreement to globally develop and commercialize...
General images of ESMO 2019 Congress being held in Barcelona, Spain, September 27 - October 1, 2019. Courtesy European Society for Medical Oncology (ESMO). Used with Permission.

ESMO 2020: Late-Breaking Data for HER3 Directed ADC Patritumab Deruxtecan in EGFR Mutated NSCLC

Data for patritumab deruxtecan (U3-1402; Daiichi Sankyo) and fam-trastuzumab deruxtecan-nxki* (Enhertu®; Daiichi Sankyo/AstraZeneca), two antibody-drug conjugates (ADC) based on...
Featured Image: Scientist in Biomedical Laboratory. Courtesy 2019 Fotolia. used with permission.

Phase I clinical study of SBT6050 Initiated

Activation of toll-like receptor 8 (TLR8) enhances natural killer(NK-) cell activation, increases antibody-dependent cell-mediated cytotoxicity and induces Th1 polarizing...
Featured Image Courtesy: Byondis Biopharmaceuticals (previously Synthon Biopharmaceuticals, Nijmegen, The Netherlands.

New Phase I Study Investigates [Vic-]Trastuzumab Duocarmazine + Niraparib in HER2-Expressing Solid Tumors

As part of a new study focusing on advanced targeting human epidermal growth factor receptor-2 (HER2-) expressing cancers, including...

Daiichi Sankyo and AstraZeneca to Jointly Evaluate Patritumab Deruxtecan + Osimertinib in EGFR-Mutated...

Earlier this week Daiichi Sankyo and AstraZeneca confirmed that the companies had entered into a clinical trial collaboration with...

CHMP Adopts Positive Opinion for Belantamab Mafodotin, Recommending Approval for the Treatment of R/R...

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive...